Morepen Laboratories Limited

MOREPENLAB

INE083A01026

Pharmaceuticals

Market Closed - Bombay S.E. Other stock markets 11:00:52 14/06/2024 BST			5-day change	1st Jan Change
56.09 ^INR	+7.72%		+16.68%	+15.58%

05-21	Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	CI
03-30	Morepen Laboratories Limited Announces Resignation of Lalit Kumar Baregama, Chief Growth Officer	CI

Morepen Laboratories Ltd. Announces Executive Changes

July 16, 2013 at 02:05 pm

Morepen Laboratories Ltd. informed that Mr. Rahul has ceased to be Company Secretary & Compliance Officer of the company, effective July 06, 2013 at the close of working hours. Mr. Ajay Kumar Sharma has been appointed as new Compliance Officer of the company.

Latest news about Morepen Laboratories Limited

Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2024	05-21	CI
Morepen Laboratories Limited Announces Resignation of Lalit Kumar Baregama, Chief Growth Officer	03-30	CI
Morepen Laboratories Limited Announces the Promotion of Amita Sharma to Chief Operating Officer -API	03-01	CI
Morepen Laboratories Limited Approves the Appointment of Vikas Sharma, Talent Acquisition & HRBP, Functional Head	01-31	CI
Morepen Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	01-31	CI
Morepen Laboratories Limited Announces Resignation of Rolli Saxena, General Manager - HR, Being A Functional Head and Senior Management Personnel	12-01	CI
Morepen Laboratories Limited Appoints Shantanu Tuli as President -Strategy and Brand Identity, Effective from December 1, 2023	11-30	CI
Morepen Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	11-02	CI
Morepen Laboratories to Transfer Formulation Distribution and Marketing Business to Subsidiary	15/08/23	MT
Morepen Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	05/08/23	CI
Morepen Laboratories' Net Profit Drops in Fiscal Q4	16/05/23	MT
Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	16/05/23	CI
US FDA Clears Morepen Laboratories' Baddi, India	27/03/23	MT
Morepen Laboratories Forms Wholly-Owned Subsidiary	20/03/23	MT
Morepen Laboratories Limited Announces Incorporation of Wholly Owned Subsidiary	17/03/23	CI
Morepen Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/02/23	CI
Morepen Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	10/11/22	CI
Morepen Laboratories Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	29/07/22	CI
Morepen Laboratories Limited Announces Resignation of Anju Suri as Director (Non-Executive, Non-Independent)	22/06/22	CI
Morepen Laboratories Limited announced that it has received INR 1.1465201 billion in funding from a group of investors	08/05/22	CI
Morepen Laboratories Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2022	05/05/22	CI
Morepen Laboratories Sees Drop in Fiscal Q4 Consolidated Net Profit	05/05/22	MT
Morepen Laboratories Limited Reports Earnings Results for the Full Year Ended March 31, 2022	05/05/22	CI
Morepen Laboratories Limited Announces Cessation of Arun Kumar Sinha as Whole Time Director	01/04/22	CI
Morepen Laboratories Posts Decline in Fiscal Q3 Consolidated Net Profit	09/02/22	MT

Chart Morepen Laboratories Limited

Duration

Period

More charts

Company Profile

Morepen Laboratories Limited is a pharmaceutical company. The Company is in the business of manufacturing, producing, developing and marketing a range of active pharmaceutical ingredients (APIs), branded and generic formulations and also home health products. Its APIs include Apixaban, Edoxaban, Linagliptin, Linagliptin + Metformin, Empagliflozin, Empagliflozin + Metformin, Atorvastatin, Rosuvastain, Rivaroxaban, Febuxostat, Montelukast (Oral), Montelukast (Chewable), among others. Its finished formulations include Intebact Capsules, Intelicaps Lax, Rythmix Kid Drop, Rythmix Kid Syrup, Kompact Powder, Saltum and Acifix 3X Suspension among others. Its home health products include Dr. Morepen 49W Room Air Purifier with HEPA Filter, Dr. Morepen VP06 Breathe Free Vaporizer, Dr. Morepen CN06 Compressor Nebulizer and Dr. Morepen ST03 Dual Head Stethoscope, among others. Its subsidiaries include Dr. Morepen Limited, Morepen Devices Limited, and Total Care Limited.

Sector

Pharmaceuticals

Calendar

24/07/2024 - Q1 2025 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MOREPEN LABORATORIES LIMITED	+15.58%	343M
NOVO NORDISK A/S	+41.96%	630B
JOHNSON & JOHNSON	-7.15%	350B
MERCK & CO., INC.	+18.77%	328B
ABBVIE INC.	+8.79%	298B
ASTRAZENECA PLC	+18.02%	246B
ROCHE HOLDING AG	+1.27%	225B
NOVARTIS AG	+11.95%	218B
AMGEN INC.	+3.68%	160B
PFIZER, INC.	-4.38%	156B

Other Pharmaceuticals

Morepen Laboratories Limited

Equities

MOREPENLAB

INE083A01026

Pharmaceuticals

Morepen Laboratories Ltd. Announces Executive Changes

Latest news about Morepen Laboratories Limited

Chart Morepen Laboratories Limited

Company Profile

Income Statement Evolution

Sector Other Pharmaceuticals